Current Studies
This study is aimed at investigating variables in combination recanalization therapies for acute, large vessel ischemic stroke that are associated with better clinical outcomes (measured by NIH stoke scale and modified Rankin Scale). Identification of these variable could potentially improve...
View Details
Current Studies
Primary Outcome Measures
Incidence of adverse events following administration of BBP-671 (Time Frame= 43 day)
BBP-671 concentration dependent change in change from baseline in QTcF (Time Frame= 43 days)
Pharmacokinetic Assessments: Cmax (Time Frame= 43 days)
Time to maximum concentration...
View Details
Current Studies
OBJECTIVES:
Develop Integrated Biomedical Computing Tools (IBCT) for the better understanding and treatment of pancreatic cancer by using the power of computer and informatics sciences.
Continue development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure to act as a...
View Details
Current Studies
Determine if early treatment with dronedarone is superior to usual care for the prevention of cardiovascular hospitalization or death from any cause in patients with first-detected atrial fibrillation.
View Details
Current Studies
- Objective: To compare pathologic complete
response (pCR) rates obtained in Arm A
(preoperative pembrolizumab and
RC+PLND) and Arm B (RC+PLND), based
on central pathologic review, evaluated in
participants whose tumors express PD-L1
CPS ≥10 and all participants, irrespective of
CPS score.
-...
View Details
Current Studies
Primary Outcome Measures:
Accuracy of PCL diagnosis [Time Frame: 48 months]
Diagnostic accuracy of confocal laser endomicroscopy and/or cyst fluid molecular markers and/or composite clinical and imaging features for the diagnosis of mucinous PCLs, PCLs with malignant potential, specific PCL types,...
View Details
Current Studies
Primary Objective:
To estimate subsequent recurrence-free survival (RFS) at 3 years for ribociclib when administered with ET (AIs or fulvestrant), in patients with Hormone Receptor (HR) positive, HER2 negative breast cancer with adequately resected local recurrence of early breast cancer...
View Details
Current Studies
Primary Objectives
To compare the complete response rate at 6 cycles after randomization as defined by centrally read PET/CT (integral biomarker) of 2 targeted therapeutic regimens (obinutuzumab + TGR-1202 or obinutuzumab + lenalidomide) with obinutuzumab + CHOP in patients with early relapsing or...
View Details
Current Studies
Primary Outcome Measures :
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 [ Time Frame: From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to...
View Details
Current Studies
Primary Outcome Measures :
Objective Response Rate (ORR) [ Time Frame: 24 months ]
ORR will be measured from the date of enrollment to date of progression (in months) based on RECIST 1.1 criteria. The analysis will include patients with PD-L1 expression TPS≥1-49 percent and TPS≥50...
View Details
Current Studies
Primary Outcome Measures:
*Safety of patient management pathway - Proportion of medication interventions with associated medication intervention related serious adverse events (Time Frame: Up to 3 years)
*The proportion of medication interventions with one or more associated medication...
View Details
Current Studies
PRIMARY OBJECTIVE
To assess the effect of in-hospital initiation of
dapagliflozin, as compared with placebo, on
the clinical outcomes of cardiovascular death
or worsening heart failure in patients who have been stabilized during
hospitalization for acute heart failure.
To evaluate the safety and...
View Details
Current Studies
Primary Objective: To determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the...
View Details
Current Studies
Primary
An Excision of the targeted lesion in a single specimen
Secondary
Rate of R0 resection Time Frame 3-4 hours
when all vertical and horizontal margins are negative
Rate of R1 resection Time Frame 3-4 hours
complete resection with no grossly visible lesion defined by...
View Details
Current Studies
Primary:
* To identify risk factors in patient history among patients evaluated at the Fall Prevention Clinic.
Secondary:
* To compare the characteristics of adult patients who experience falls v/s those who do not.
* To review findings on examination (general and neurological) and testing...
View Details
Current Studies
Primary
The primary objective of this Phase 2 study is to evaluate the safety of Epcoritamab monotherapy without mandatory hospitalization for the first full dose of Epcoritamab in subjects with R/R DLBCL or R/R FL Grade 1-3a who have received at least 2 prior lines of systemic anti-lymphoma...
View Details
Current Studies
Primary Outcome Measures :
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10 [ Time Frame: Up to approximately 33 months ]
PFS is defined as the...
View Details
Current Studies
1) Complete closure rate: proportion of cases in which complete tissue approximation is achieved with the use of the DAT clip (no substantial gaps are visible in the closure line)
2) Achievement of intended targeted therapy: defined as cases in which utilization of the DAT clip accomplished the...
View Details
Current Studies
Primary Objective/Aim/Goal/Hypothesis
Aim. The primary aim is to evaluate the efficacy of the SAP gel in the prevention of stricture formation following endoscopic resection in high-risk patients
View Details
Current Studies
Primary Objective
Compare conventional radiological progression-free survival (rPFS) for positron emission tomography (PET)-detected, biochemically recurrent, oligometastatic, castration-sensitive prostate cancer patients treated with SABR plus placebo vs. SABR plus relugolix.
Secondary...
View Details
Current Studies
3.1 Primary Objective:
To compare the effectiveness of two approaches for the management of Barrett s esophagus (BE) and low-grade dysplasia (LGD), endoscopic surveillance and endoscopic eradication therapy (EET), using an accepted clinical endpoint of neoplastic progression [high-grade dysplasia...
View Details
Current Studies
Aim of study: to examine outcomes and complications of rectal ESDs performed within 2 cm of the dentate line
Primary endpoints: to determine the rate of R0 resection of rectal ESDs performed within 2 cm of the dentate line
Secondary endpoints: to determine complication rates of rectal ESDs...
View Details
Current Studies
Our objective with this study is to take a retrospective look at patients with achalasia in the state of Indiana who have undergone either surgical therapy via laparoscopic or open Heller myotomy, or endoscopic therapy with the Per-oral endoscopic myotomy (POEM) procedure. We plan to compare the...
View Details
Current Studies
To offer NODE-301, NODE-302 and NODE-303 subjects continued access to Etripamil
View Details
Current Studies
Primary Objective
ctDNA-ve Cohort (Arms 1 + 2):
Phase II: To compare time to ctDNA (+ve) status in ctDNA (-ve) cohort following resection of stage III colon cancer treated with immediate vs delayed (based on serial ctDNA surveillance) chemotherapy. Time to positive event is defined as time from...
View Details
Current Studies
Primary objective
To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant mFOLFOX6.
Secondary objective(s)
To evaluate and compare organ-preservation-time...
View Details
Current Studies
Primary Objective:
To evaluate the impact of Envisia on:
* Treatment decision: Increase in proportion of patients prescribed anti-fibrotics in those with an Envisia UIP+ result versus their pre-Envisia plan.
Secondary Objectives:
To evaluate the impact of Envisia on:
* Diagnosis: Increase in...
View Details
Current Studies
The primary objective is to evaluate whether invasive procedures in the group classified as low-risk by the Percepta Nasal Swab test and that are benign are reduced in the test group who received a Percepta Nasal Swab result as compared to the control group who were managed without a Percepta Nasal...
View Details
Current Studies
Analyze the outcomes of endoscopic esophageal stent placement in those with esophageal cancer
View Details
Current Studies
Primary: Determine the safety of a single administration of HMI-103
To evaluate the efficacy of HMI-103on reduction of plasma Pheconcentration at each dose level
View Details